Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Target

B-cell lymphoma 2 (BCL-2)

2 abstracts

Abstract
Preliminary data of a phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
Org: Ascentage Pharma (Suzhou) Co., Ltd., Ascentage Pharma Group, Jiangsu Ascentage Pharma Pty Ltd.,
Abstract
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).
Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,